A Phase III, radonmized, double-blinded, parallel group, multi centre study to access the efficacy and safety of ZD6474 (ZACTIMA TM) in combination with pemetrexed (Alimta) versus pemetrexed alone in patients with locally-advanced or metastatic (stage IIIB or IV) non-small cell lung cancer (NSCLC) after failure of 1st line anti-cancer therapy
Grant Data
Project Title
A Phase III, radonmized, double-blinded, parallel group, multi centre study to access the efficacy and safety of ZD6474 (ZACTIMA TM) in combination with pemetrexed (Alimta) versus pemetrexed alone in patients with locally-advanced or metastatic (stage IIIB or IV) non-small cell lung cancer (NSCLC) after failure of 1st line anti-cancer therapy
Principal Investigator
Dr Ho, James Chung Man
(Principal Investigator (PI))
Co-Investigator(s)
Dr Wong King Yan Matthew
(Co-Investigator)
Dr Lam David Chi Leung
(Co-Investigator)
Dr Wang Julie Kwan Ling
(Co-Investigator)
Duration
31
Start Date
2007-02-01
Amount
337838
Conference Title
A Phase III, radonmized, double-blinded, parallel group, multi centre study to access the efficacy and safety of ZD6474 (ZACTIMA TM) in combination with pemetrexed (Alimta) versus pemetrexed alone in patients with locally-advanced or metastatic (stage IIIB or IV) non-small cell lung cancer (NSCLC) after failure of 1st line anti-cancer therapy
Presentation Title
Keywords
locally-advanced, metastatic (stage IIIB or IV) NSCLC
Discipline
Respiration,Cancer
HKU Project Code
N/A
Grant Type
Pharmaceutical Industry - General Award
Funding Year
2006
Status
On-going